

## ErbB-3 (RTJ.2): sc-415

### BACKGROUND

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Full length ErbB-3 is overexpressed in human mammary tumors. The ErbB-3 gene also produces several alternative variants, including a secreted form of which negatively regulates heregulin-stimulated ErbB activation. ErbB-3 heterodimerizes with Neu and binds heregulin in order to activate phosphoinositide (PI) 3-kinase. The recruitment and activation of PI 3-kinase occurs via its interaction with phosphorylated YXXM motifs in the carboxy terminus of ErbB-3.

### CHROMOSOMAL LOCATION

Genetic locus: ERBB3 (human) mapping to 12q13.2; Erbb3 (mouse) mapping to 10 D3.

### SOURCE

ErbB-3 (RTJ.2) is a mouse monoclonal antibody epitope mapping within the cytoplasmic domain of ErbB-3 of human origin.

### PRODUCT

Each vial contains 200 µg IgG<sub>1</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

ErbB-3 (RTJ.2) is available conjugated to agarose (sc-415 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-415 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-415 PE), fluorescein (sc-415 FITC), Alexa Fluor<sup>®</sup> 488 (sc-415 AF488), Alexa Fluor<sup>®</sup> 546 (sc-415 AF546), Alexa Fluor<sup>®</sup> 594 (sc-415 AF594) or Alexa Fluor<sup>®</sup> 647 (sc-415 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor<sup>®</sup> 680 (sc-415 AF680) or Alexa Fluor<sup>®</sup> 790 (sc-415 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor<sup>®</sup> is a trademark of Molecular Probes, Inc., Oregon, USA

### APPLICATIONS

ErbB-3 (RTJ.2) is recommended for detection of ErbB-3 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10<sup>6</sup> cells).

Suitable for use as control antibody for ErbB-3 siRNA (h): sc-35327, ErbB-3 siRNA (m): sc-35328, ErbB-3 shRNA Plasmid (h): sc-35327-SH, ErbB-3 shRNA Plasmid (m): sc-35328-SH, ErbB-3 shRNA (h) Lentiviral Particles: sc-35327-V and ErbB-3 shRNA (m) Lentiviral Particles: sc-35328-V.


Molecular Weight of ErbB-3: 180 kDa.

Positive Controls: ErbB-3 (h): 293T Lysate: sc-111418, T-47D cell lysate: sc-2293 or SK-BR-3 cell lysate: sc-2218.


### STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### DATA



ErbB-3 (RTJ.2): sc-415. Western blot analysis of ErbB-3 expression in non-transfected: sc-117752 (A) and human ErbB-3 transfected: sc-111418 (B) 293T whole cell lysates.



ErbB-3 (RTJ.2): sc-415. Immunofluorescence staining of methanol-fixed HeLa cells showing membrane localization.

### SELECT PRODUCT CITATIONS

- Kramer, R., et al. 1996. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. *Proc. Natl. Acad. Sci. USA* 93: 4833-4838.
- Navarrete Montalvo, D., et al. 2008. Patterns of recurrence and survival in breast cancer. *Oncol. Rep.* 20: 531-535.
- Almadori, G., et al. 2010. Prognostic significance and clinical relevance of the expression of the HER family of type I receptor tyrosine kinases in human laryngeal squamous cell carcinoma. *Eur. J. Cancer* 46: 1144-1152.
- Jay, S.M., et al. 2011. Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. *J. Biol. Chem.* 286: 27729-27740.
- Steinkamp, M.P., et al. 2014. ErbB3 is an active tyrosine kinase capable of homo- and heterointeractions. *Mol. Cell. Biol.* 34: 965-977.
- Farkkila, A., et al. 2014. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor—a long-term follow-up study. *Cancer Med.* 3: 526-536.
- Yang, X., et al. 2014. Characterization of EGFR family gene aberrations in cholangiocarcinoma. *Oncol. Rep.* 32: 700-708.
- Xi, Y., et al. 2015. Induction of Bcl2-interacting killer, BIK, is mediated for anti-cancer activity of curcumin in human head and neck squamous cell carcinoma cells. *J. Cancer* 6: 327-332.
- Chong, Q.Y., et al. 2017. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2<sup>+</sup>/ER<sup>+</sup> mammary carcinoma. *Oncotarget* 8: 74188-74208.
- Ribas, R., et al. 2018. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. *Breast Cancer Res.* 20: 44.

### RESEARCH USE

For research use only, not for use in diagnostic procedures.